Tao Shuang, Bai Zhengyang, Liu Yaobang, Gao Yali, Zhou Jia, Zhang Yangyang, Li Jinping
Department of Breast Surgery, Wu Jin Hospital of Jiangsu University, Changzhou 213000, China.
Ningxia Medical University, Yinchuan 750004, China.
J Oncol. 2022 Jun 30;2022:5483523. doi: 10.1155/2022/5483523. eCollection 2022.
Chemoresistance poses a great hindrance in the treatment of breast cancer (BC). Interestingly, exosome (Exo)-mediated transfer of long noncoding RNAs (lncRNAs) has been reported to regulate chemoresistance in diverse diseases. We herein investigate the potential role of lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) transferred by BC cell-derived Exo in chemoresistance of BC cells.
BC-related lncRNAs were identified. Exosomes were isolated and verified from BC cells. The expression patterns of MALAT1 were then examined in the adriamycin (ADR)-sensitive and resistant cells and the isolated Exo, followed by the analysis of the downstream microRNA (miRNA) of MALAT1. The role and mechanism of MALAT1 transmitted by BC cell-derived Exo in BC cell metastasis and chemoresistance were assessed.
MALAT1 was highly expressed in BC cells and their Exo. In addition, MALAT1 delivered by BC cell-derived Exo augmented the malignant properties and chemoresistance of BC cells. Mechanistically, MALAT1 bound to miR-1-3p and limited the miR-1-3p expression, which sequentially targeted the vasodilator-stimulated phosphoprotein (VASP) protein. Moreover, silencing of VASP inhibited the activation of the RAP1 member of RAS oncogene family (Rap1) signaling pathway, which led to the attenuation of BC cell malignant properties and chemoresistance. assay further validated the tumor-promoting effect of Exo-MALAT1 regulation of the miR-1-3p/VASP/Rap1 axis.
Collectively, MALAT1 loaded by BC cell-derived Exo can accelerate BC cell metastasis and chemoresistance disruption of miR-1-3p-mediated inhibition of the VASP/Rap1 signaling axis.
化疗耐药是乳腺癌(BC)治疗中的一大障碍。有趣的是,据报道,外泌体(Exo)介导的长链非编码RNA(lncRNA)转移可调节多种疾病中的化疗耐药性。我们在此研究BC细胞来源的Exo所转移的lncRNA转移相关肺腺癌转录本1(MALAT1)在BC细胞化疗耐药中的潜在作用。
鉴定与BC相关的lncRNA。从BC细胞中分离并验证外泌体。然后检测阿霉素(ADR)敏感和耐药细胞以及分离出的外泌体中MALAT1的表达模式,随后分析MALAT1的下游微小RNA(miRNA)。评估BC细胞来源的Exo所传递的MALAT1在BC细胞转移和化疗耐药中的作用及机制。
MALAT1在BC细胞及其外泌体中高表达。此外,BC细胞来源的Exo所传递的MALAT1增强了BC细胞的恶性特性和化疗耐药性。机制上,MALAT1与miR-1-3p结合并限制miR-1-3p的表达,miR-1-3p依次靶向血管舒张刺激磷蛋白(VASP)蛋白。此外,VASP的沉默抑制了RAS癌基因家族(Rap1)信号通路中RAP1成员的激活,这导致BC细胞恶性特性和化疗耐药性减弱。实验进一步验证了Exo-MALAT1对miR-1-3p/VASP/Rap1轴的调节具有促进肿瘤的作用。
总体而言,BC细胞来源的Exo所负载的MALAT1可通过破坏miR-1-3p介导的对VASP/Rap1信号轴的抑制作用来加速BC细胞转移和化疗耐药。